OncoPrecision is an oncology therapeutics company developing precision medicines to give patients transformational options — guided by their biology, defined by their lives.
Why We Do This
More mornings like this one. That's the point.
Blood cancers and hard-to-treat solid tumors cut short too many lives — not for lack of effort, but for lack of therapies that reach the right biology at the right time. We are building those therapies. Every target we choose, every program we advance, begins and ends with the patients waiting for an answer.
Live · year to date
—
New cancer diagnoses worldwide so far this year.
About 38 per minute, worldwide. Source: WHO IARC GLOBOCAN (2022 estimates).
Live · year to date
—
Patients facing cancer relapse worldwide so far this year.
About 11 per minute, worldwide. Estimated from global incidence and average relapse rates across cancer types.
Our Differentiation
Three forces, one mission.
Patient-Derived Biology
Patient Micro-Avatars™
Our targets are identified from real patient tumor biology — not population databases. We start where resistance is already happening.
AI-Enhanced Discovery
Computational modeling accelerates target validation and antibody optimization — compressing the timeline from insight to clinical candidate.
First-in-Class Audacity
Antibody-drug conjugates and bispecific antibodies engineered to exploit vulnerabilities that existing therapies cannot reach — taking bold first steps to tackle novel biology, starting with CD64.
Medicines with a higher probability of clinical success begin at the center.
Our Differentiation
Three forces, one mission.
Patient-Derived Biology
Patient Micro-Avatars™
Our targets are identified from real patient tumor biology — not population databases. We start where resistance is already happening.
AI-Enhanced Discovery
Computational modeling accelerates target validation and antibody optimization — compressing the timeline from insight to clinical candidate.
First-in-Class Audacity
Antibody-drug conjugates and bispecific antibodies engineered to exploit vulnerabilities that existing therapies cannot reach — taking bold first steps to tackle novel biology, starting with CD64.
Each of our programs is built on the convergence of patient-derived biology, AI-enhanced discovery, and first-in-class audacity.
Medicines with a higher probability of clinical success begin at the center.
Our Approach
Discovery built on the biology of resistance.
We start where other drugs fail — studying how cancer cells evade treatment — then engineer precision therapeutics to exploit those vulnerabilities.
Discovery Framework
By combining our Patient Micro-Avatars™ with AI-driven target validation across billions of phenotypic data points, our discovery engine surfaces biology that population-level datasets miss — giving every program a structural advantage from day one.
01
Patient Tumor Biology
Every program begins in our Patient Micro-Avatars™ — translational models built from real patient samples — so resistance mechanisms emerge from disease biology rather than population averages.
02
AI-Enhanced Target Validation
AI mines billions of translational phenotypic data points from those models, surfacing the most tractable vulnerabilities and shortening the path from biological insight to lead candidate.
03
Modality Engineering
After identifying the top target, patient biology guides whether an ADC or bispecific best fits the desired target product profile. From lead antibody to linker and payload, every decision is anchored in translation, not trends.
04
First-in-Class Development Candidate
By the time we nominate a development candidate, patient biology has shaped every decision — building high conviction in its real-world impact long before the first patient is dosed.
Pipeline
Patient-centric by design.
An antibody-based pipeline seeking to drive a step change in cancers and inflammatory diseases that have been historically hard to treat.
ONC001
CD64-ADC
Monocytic Leukemia · Solid Tumors
CD64 is a myeloid-restricted receptor broadly expressed across chronic myelomonocytic leukemia (CMML) and acute monocytic leukemia (M4/M5 FAB AML), including disease subsets that are highly resistant to standard therapy — yet it remains an untapped therapeutic target.
ONC001 is a first-in-class ADC engineered to exploit this vulnerability. Its high-affinity antibody is paired with a payload and linker optimized to minimize off-target toxicity and preserve healthy hematopoiesis, offering a precision-targeted approach to disrupt monocyte-driven resistance where effective options are limited.
Currently in IND-Enabling Studies
Development Candidate nominated
Full pipeline
First-in-class ADCs and BsAbs. Bold biology, outsized impact.
ONC001
LeadCD64-ADC
Monocytic Leukemia · Solid Tumors
Currently in IND-Enabling Studies
Development Candidate nominated
ONC002
ADC / BsAb
Solid Tumors · Immunity & Inflammation
Currently in Preclinical Development
ONC007
ADC / BsAb
Multiple Myeloma
Currently in Target Validation
Our Team
Driven by purpose.
Our team brings decades of oncology drug discovery, development, immunology, and clinical translation experience — united by the conviction that the most important cancers are the ones with no good answers yet.
Alejandra García, PhD
Head of Biology
Candelaria Llorens, PhD
Co-FounderHead of Operations
Cintia Garro, PhD
Staff Scientist
Constanza Marin, PhD
Staff Scientist
Diego Andino, MSc
Senior Data Scientist
Federico Rusculleda
Admin Manager
Gastón Soria, PhD
Co-FounderCSO
Gerardo Gatti, PhD
Co-FounderHead of Clinical Research
Han Myint, MD, FACP
Fractional CMO
Laura Bertoldi, PhD
Lab Manager
Lia Buffa
Research Associate III
Tarek Zaki
Co-FounderCEO
Our Advisors
Visionary leaders from the bench, the clinic, and the corporation.
Arthur Tinkelenberg, PhD
Principal Owner
OurPlanet LLC
Francisco Molinari
Former CEO
AMEGA Biotech
Gail Roboz, MD
Director of Clinical and Translational Leukemia
Weill Cornell Medicine and NewYork-Presbyterian Hospital
Gwen Nichols, MD
EVP & Chief Medical Officer
Blood Cancer United
Israel Gloger, OBE, PhD, FRSB
Founder Emeritus
Trust in Science, GSK
Jorge Solimano, MD
Head of Hematology
CEMIC
Robert Schneider, PhD
Associate Dean for Therapeutics Alliances
NYU Langone Health
Stefan Oschmann, PhD
Former Chairman & CEO
Merck KGaA
Our Investors
Backed by partners who share our conviction.
Our Values
The principles that guide every decision.
Adaptive Momentum
We always prioritize action over inertia, even when navigating complex shifts.
Cross the Finish Line
We execute all the way and don't leave work half-finished.
Led by Patients
Patient biology guides our decisions and we choose the path of maximum patient impact.
Collective Genius
We optimize collaboration over individual agendas, egos, or functional silos to succeed.
Forged Resilience
We embrace adversity and emerge stronger from the challenges we overcome.
Partnerships
Build first-in-class therapies with us.
OncoPrecision pairs patient-derived biology with AI-enhanced discovery to find what others miss. We're open to pharmaceutical partners who want to move with conviction — whether that means co-discovering novel targets on our platform or licensing our first-in-class programs.
Co-Discovery
Leverage our platform to validate targets and define optimal therapeutic modalities across leukemia and multiple myeloma. You bring scale, development engine, and reach. We bring patient-derived biology and AI-enhanced discovery.
Licensing
Access our pipeline of first-in-class ADCs and bispecific antibodies across hematology and solid tumors. Our programs are engineered for precision and built with clinical translation at the center.
Publications
Our work, presented where the field gathers.
Abstracts and presentations at the American Society of Hematology (ASH) and the American Association for Cancer Research (AACR) — sharing what our platform is uncovering with the broader oncology community.
AACR 2026
ASH 2025
ASH 2024
- Poster
Ex-Vivo Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Acute Myeloid Leukemia
Craig A. Leach, et al.
- Online Publication
Blinded Ex-Vivo Testing in AML Reveals Differences between Hypomethylating Agents When Combined with Venetoclax
Dunay Bach, et al.
- Online Publication
Ex-Vivo Testing of Myeloma Cells and Autologous Effector Cells from the Tumor Microenvironment Unveils Differential Response to Daratumumab and Isatuximab
Constanza Marin, et al.
ASH 2023
- Poster
Ex-Vivo Testing Platform to Predict Clinical Response and Resistance to Proteasome Inhibitors, IMiDs and Daratumumab in Multiple Myeloma
Constanza Marin, et al.
- Poster
Functional Ex-Vivo Testing Combined with Machine Learning Predicts Clinical Response to Azacitidine+Venetoclax in AML
Diego Andino, et al.
- Online Publication
A Single Phenotypic Biomarker of Gemtuzumab Ozogamicin (GO) Response in Acute Myeloid Leukemia Using Ex-Vivo Testing
Cintia Garro, et al.
- Online Publication
Identification of Unexpected Responders to Gilteritinib in a Cohort of FLT3-WT AML Patients Using Ex-Vivo Testing
Alejandra García, et al.
ASH 2022
Latest
News.
Company Announcement
OncoPrecision Co-Founder & CSO Gastón Soria to speak on translational ADC design at the 4th Annual ADC Linker & Conjugation Summit
July 2026 · 4th Annual ADC Linker & Conjugation Summit
Read moreCompany Announcement
OncoPrecision presents preclinical data on ONC001, a first-in-class CD64-targeting ADC, at AACR 2026
April 2026 · AACR Annual Meeting
Read morePress Release
OncoPrecision delivers oral presentation on ONC001, a first-in-class CD64-targeting ADC for monocytic leukemia, at ASH 2025
December 2025 · 67th ASH Annual Meeting
Read more
Contact
Let's talk.
Whether you're a potential partner, a prospective teammate, or just curious about what we're building, we'd love to hear from you. Pick a track on the right and we'll get back to you.